Tazeen Ahmad
Stock Analyst at B of A Securities
(3.36)
# 986
Out of 4,967 analysts
208
Total ratings
47.71%
Success rate
3.25%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $706.50 | +25.55% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $18.27 | -12.42% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $52.21 | +45.57% | 19 | Aug 20, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $99.38 | +34.84% | 9 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $23 → $24 | $28.15 | -14.74% | 8 | Jul 16, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $336 → $359 | $449.71 | -20.17% | 4 | Jul 11, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | $8 | $2.87 | +178.75% | 1 | Jul 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $73 → $95 | $105.50 | -9.95% | 9 | Jul 10, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Buy | $13 → $15 | $8.31 | +80.51% | 12 | Jul 1, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $201 → $216 | $201.86 | +7.00% | 10 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $23 | $26.10 | -11.88% | 15 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $8.21 | -51.28% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.95 | -16.01% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $15.09 | +78.93% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $7.67 | +265.06% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $66.19 | +5.76% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $6.08 | +557.89% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $141.53 | +26.47% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.25 | +54.39% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.21 | +147.93% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $86.46 | +4.09% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.72 | +94.30% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $6.51 | -69.28% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $31.12 | +144.22% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.09 | +379.62% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.04 | +476.92% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.40 | +21.02% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $22.79 | -51.73% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.08 | -35.06% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.19 | +406.33% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $12.50 | +20.00% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $45.50 | +31.88% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.29 | +1,140.31% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $9.10 | +372.53% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $209.97 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.16 | +3,175.11% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.08 | +332.69% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $27.06 | +77.38% | 6 | Oct 10, 2018 |
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $706.50
Upside: +25.55%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $18.27
Upside: -12.42%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $52.21
Upside: +45.57%
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $99.38
Upside: +34.84%
Apellis Pharmaceuticals
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $28.15
Upside: -14.74%
Alnylam Pharmaceuticals
Jul 11, 2025
Maintains: Buy
Price Target: $336 → $359
Current: $449.71
Upside: -20.17%
Taysha Gene Therapies
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $2.87
Upside: +178.75%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $105.50
Upside: -9.95%
BioCryst Pharmaceuticals
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.31
Upside: +80.51%
Ascendis Pharma
Jun 9, 2025
Maintains: Buy
Price Target: $201 → $216
Current: $201.86
Upside: +7.00%
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $26.10
Upside: -11.88%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $8.21
Upside: -51.28%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.95
Upside: -16.01%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $15.09
Upside: +78.93%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.67
Upside: +265.06%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $66.19
Upside: +5.76%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $6.08
Upside: +557.89%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $141.53
Upside: +26.47%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $14.25
Upside: +54.39%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.21
Upside: +147.93%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $86.46
Upside: +4.09%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.72
Upside: +94.30%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $6.51
Upside: -69.28%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $31.12
Upside: +144.22%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.09
Upside: +379.62%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.04
Upside: +476.92%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.40
Upside: +21.02%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $22.79
Upside: -51.73%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.08
Upside: -35.06%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.19
Upside: +406.33%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $12.50
Upside: +20.00%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $45.50
Upside: +31.88%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.29
Upside: +1,140.31%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $9.10
Upside: +372.53%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $209.97
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.16
Upside: +3,175.11%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.08
Upside: +332.69%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $27.06
Upside: +77.38%